2013
The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial
Meier P, Lansky AJ, Fahy M, Xu K, White HD, Bertrand ME, Mehran R, Stone GW. The impact of the coronary collateral circulation on outcomes in patients with acute coronary syndromes: results from the ACUITY trial. Heart 2013, 100: 647. PMID: 24310521, DOI: 10.1136/heartjnl-2013-304435.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedCollateral CirculationCoronary AngiographyCoronary Artery BypassCoronary CirculationFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsProportional Hazards ModelsRisk FactorsTime FactorsTreatment OutcomeConceptsMajor adverse cardiac eventsAcute coronary syndromeTarget vessel revascularisationPercutaneous coronary interventionAdverse cardiac eventsCoronary collateral circulationMyocardial infarctionCoronary syndromeCardiac eventsClinical outcomesCollateral circulationHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialIndependent angiographic core laboratorySubgroup of patientsCoronary collateral vesselsAngiographic core laboratoryPresence of collateralsACUITY trialAcute CatheterizationRentrop scoreVessel revascularisationMultivariable adjustmentCoronary interventionVisible collateralsRelationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention
Farkouh ME, Reiffel J, Dressler O, Nikolsky E, Parise H, Cristea E, Baran DA, Dizon J, Merab JP, Lansky AJ, Mehran R, Stone GW. Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation Cardiovascular Interventions 2013, 6: 216-223. PMID: 23652600, DOI: 10.1161/circinterventions.112.000142.Peer-Reviewed Original ResearchMeSH KeywordsAgedChi-Square DistributionCoronary AngiographyElectrocardiographyFemaleFibrinolytic AgentsHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsRecovery of FunctionRisk FactorsStentsTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionPrimary PCIMajor adverse cardiovascular eventsST-segment resolutionAdverse cardiovascular eventsIschemia-driven target vessel revascularizationComplete ST-segment resolutionTarget vessel revascularizationPercutaneous coronary interventionMyocardial infarctionCardiovascular eventsVessel revascularizationCoronary interventionIndependent predictorsDegree of STRBaseline ST-segment elevationAcute Myocardial Infarction trialLong-term prognostic valueLong-term cardiovascular mortalityLeft ventricular ejection fractionLong-term predictive valuePost-PCI electrocardiogramsMyocardial infarction (TIMI) flowMyocardial Infarction trial
2012
Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens
Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens. Circulation Cardiovascular Interventions 2012, 5: 157-165. PMID: 22354934, DOI: 10.1161/circinterventions.111.963876.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overBiomarkersFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHumansKidney Failure, ChronicMaleMyocardial InfarctionPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsReference StandardsSurvival AnalysisTroponin TConceptsGlycoprotein IIb/IIIa inhibitorsAcute coronary syndromeBaseline troponin elevationChronic kidney diseaseMajor adverse cardiac eventsTroponin elevationMyocardial infarctionBivalirudin monotherapyMajor bleedingCKD patientsCoronary syndromeBaseline troponinKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsLong-term clinical outcomesBaseline cardiac troponinBaseline troponin levelsDifferent antithrombotic regimensAdverse cardiac eventsACS patientsACUITY trialAntithrombotic regimensComposite deathRandomization arm
2011
Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.
Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. EuroIntervention 2011, 7: 905-16. PMID: 22157475, DOI: 10.4244/eijv7i8a144.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingMyocardial infarctionTF approachMajor adverse cardiovascular eventsNet adverse clinical eventsAdverse cardiovascular eventsEvent-free survivalAdverse clinical eventsPercutaneous coronary interventionImproved clinical outcomesAcute myocardial infarctionOne-year ratesRate of deathPaucity of dataComposite deathHORIZONS-AMICardiovascular eventsPrimary angioplastyAnticoagulation regimensCoronary interventionPredictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes
Palmerini T, Dangas G, Mehran R, Caixeta A, Généreux P, Fahy MP, Xu K, Cristea E, Lansky AJ, Stone GW. Predictors and Implications of Stent Thrombosis in Non–ST-Segment Elevation Acute Coronary Syndromes. Circulation Cardiovascular Interventions 2011, 4: 577-584. PMID: 22028471, DOI: 10.1161/circinterventions.111.963884.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, Balloon, CoronaryComorbidityCoronary ThrombosisCoronary VesselsDiabetes Mellitus, Type 1Drug-Eluting StentsElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHumansMaleMetalsMiddle AgedPredictive Value of TestsPrevalenceProspective StudiesRisk FactorsStentsConceptsSegment elevation acute coronary syndromesElevation acute coronary syndromeProbable stent thrombosisAcute coronary syndromeStent thrombosisNSTE-ACSCardiac mortalityCoronary syndromeIndependent predictorsStent implantationDiseased vesselsUrgent Intervention Triage Strategy (ACUITY) trialDynamic ST segment changesIncidence of STInsulin-treated diabetes mellitusElective stent implantationEarly stent thrombosisPercutaneous coronary interventionST-segment changesBare metal stentsDrug-eluting stentsLate stent thrombosisST-segment deviationAcute CatheterizationAntithrombotic regimensLong-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 1011-1019. PMID: 21939942, DOI: 10.1016/j.jcin.2011.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionChronic DiseaseDrug-Eluting StentsEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansIsraelKaplan-Meier EstimateKidney DiseasesMaleMetalsMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsProspective StudiesProsthesis DesignRecombinant ProteinsRecurrenceRisk AssessmentRisk FactorsStentsStrokeThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionNet adverse cardiac eventsChronic kidney diseasePercutaneous coronary interventionTarget vessel revascularizationBare metal stentsDrug-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionMajor bleedingBivalirudin monotherapyCoronary interventionKidney diseaseMyocardial infarctionRate of TVRIschemia-driven target vessel revascularizationNon-coronary artery bypassIIb/IIIa inhibitorsBenefit of bivalirudinDifferent antithrombotic strategiesAdverse cardiac eventsComposite of deathHigh ratePrognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, Mehran R, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. JACC Cardiovascular Interventions 2011, 4: 769-777. PMID: 21777885, DOI: 10.1016/j.jcin.2011.02.019.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionAcute coronary syndromeACUITY trialStent thrombosisMyocardial infarctionACS patientsCoronary interventionIndependent predictorsHigh-risk acute coronary syndromesSegment elevation acute coronary syndromesElevation acute coronary syndromeHigh-risk ACS patientsIndependent angiographic core laboratoryEpicardial coronary flowEarly invasive strategyRisk of deathHigh-risk populationAngiographic core laboratoryHigh rateBaseline angiographyCoronary syndromeIschemic complicationsAdjunctive pharmacotherapyCoronary thrombusPrognostic importanceIncidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial
Caixeta A, Dangas GD, Mehran R, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: Results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. American Heart Journal 2011, 161: 298-306.e1. PMID: 21315212, DOI: 10.1016/j.ahj.2010.10.035.Peer-Reviewed Original ResearchConceptsIIb/IIIa inhibitorsGP IIb/IIIa inhibitorsAcute coronary syndromeBivalirudin monotherapyMajor bleedingCoronary syndromePlatelet countClinical consequencesUrgent Intervention Triage Strategy (ACUITY) trialGlycoprotein IIb/IIIa inhibitorsPredictors of mortalityAcquired thrombocytopeniaACUITY trialAcute CatheterizationAntiplatelet medicationsAntithrombotic therapyIschemic complicationsAnticoagulant regimenIndependent predictorsStrategy trialThrombocytopeniaPatientsMultivariate analysisMonotherapyLess decline
2010
Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, Mehran R, Stone GW. Impact of Bivalirudin Therapy in High-Risk Patients With Acute Myocardial Infarction 1-Year Results From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2010, 3: 796-802. PMID: 20723849, DOI: 10.1016/j.jcin.2010.05.009.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsChi-Square DistributionEptifibatideEuropeFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansImmunoglobulin Fab FragmentsIsraelKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPatient SelectionPeptide FragmentsPeptidesPlatelet Aggregation InhibitorsProspective StudiesRecombinant ProteinsRisk AssessmentRisk FactorsSecondary PreventionStentsTime FactorsTreatment OutcomeUnited StatesConceptsGlycoprotein IIb/IIIa inhibitorsHORIZONS-AMI trialHigh-risk patientsAcute myocardial infarctionRecurrent myocardial infarctionUnfractionated heparinMyocardial infarctionHigh riskPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline patient riskCADILLAC risk scoreIntermediate-risk groupPrimary percutaneous interventionPercutaneous coronary interventionHigh-risk groupLow-risk groupBivalirudin therapyMajor bleedingTrial patientsCoronary interventionIntermediate riskClinical variablesPercutaneous interventionPatient riskA Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes
Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal Of The American College Of Cardiology 2010, 55: 2556-2566. PMID: 20513595, DOI: 10.1016/j.jacc.2009.09.076.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overAngioplasty, Balloon, CoronaryCause of DeathConfidence IntervalsCoronary AngiographyCoronary Artery BypassElectrocardiographyFemaleFibrinolytic AgentsHemorrhageHeparinHospital MortalityHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsProbabilityProportional Hazards ModelsRisk AssessmentSeverity of Illness IndexSurvival AnalysisTreatment OutcomeConceptsAcute coronary syndromeInteger risk scoreMajor bleedingRisk scoreCoronary syndromeNon-coronary artery bypass graft surgerySubsequent mortalityCox proportional hazards regression modelArtery bypass graft surgeryProportional hazards regression modelsMultivariable logistic regression modelHORIZONS-AMI trialPractical risk scoreBypass graft surgerySimple risk scoreIndependent baseline predictorsTreatment-related variablesHazards regression modelsAppropriate treatment strategyLogistic regression modelsGraft surgeryHemorrhagic complicationsIdentifies patientsBlood transfusionLarge hematomaImpact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial)
Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW. Impact of Anemia on Clinical Outcomes of Patients With ST-Segment Elevation Myocardial Infarction in Relation to Gender and Adjunctive Antithrombotic Therapy (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 105: 1385-1394. PMID: 20451683, DOI: 10.1016/j.amjcard.2010.01.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAngioplasty, Balloon, CoronaryCombined Modality TherapyDrug Therapy, CombinationElectrocardiographyFemaleFibrinolytic AgentsFollow-Up StudiesHeparinHirudinsHospital MortalityHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionNeoadjuvant TherapyPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProbabilityProportional Hazards ModelsRecombinant ProteinsRisk AssessmentSex FactorsSurvival AnalysisThrombolytic TherapyTreatment OutcomeConceptsST-elevation myocardial infarctionElevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsBaseline anemiaPercutaneous coronary interventionAdjunctive antithrombotic therapyMajor bleedingMyocardial infarctionAntithrombotic therapyCoronary interventionUnfractionated heparinST-segment elevation myocardial infarctionMultivariate analysisAcute Myocardial Infarction trialImpact of anemiaMyocardial Infarction trialOutcomes of patientsHarmonizing OutcomesCardiac mortalityCause mortalityLate mortalityPrimary PCIClinical outcomes
2009
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation 2009, 121: 43-51. PMID: 20026777, DOI: 10.1161/circulationaha.109.878017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk FactorsConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIndividual patient risk profileAcute coronary syndromePatient risk profileMajor bleedingMyocardial infarctionCoronary syndromeRisk profileHemorrhagic complicationsIndependent predictorsMortality rateUrgent Intervention Triage Strategy (ACUITY) trialAlternative antithrombotic regimensIndividual patient's riskRisk of deathCox regression modelTherapy of patientsSubsequent mortality ratesRelative treatment effectsAcute CatheterizationAntithrombotic regimensMajor bleedsAlternative pharmacotherapyStrategy trialOutcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials
DOLL JA, NIKOLSKY E, STONE GW, MEHRAN R, LINCOFF AM, CAIXETA A, MCLAURIN B, CRISTEA E, FAHY M, KESANAKURTHY V, LANSKY AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE‐2, ACUITY, and HORIZONS‐AMI Trials. Journal Of Interventional Cardiology 2009, 22: 453-459. PMID: 19702677, DOI: 10.1111/j.1540-8183.2009.00494.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsChemotherapy, AdjuvantCoronary VesselsDrug Therapy, CombinationFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsSurvival RateTreatment OutcomeWounds, PenetratingConceptsPercutaneous coronary interventionGP IIb/IIIa inhibitorsIIb/IIIa inhibitorsAdjunctive antithrombotic therapyUnfractionated heparinMyocardial infarctionAntithrombotic therapyCoronary interventionPCI trialProvisional glycoprotein (GP) IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitionIIb/IIIa inhibitionBaseline creatinine clearanceHORIZONS-AMI trialGP IIb/IIIaOutcomes of patientsOnly independent predictorCoronary artery perforationManagement of patientsTreatment of patientsIIb/IIIaLower ratesSimilar ratesBivalirudin monotherapyHORIZONS-AMIImpact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy
Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovascular Interventions 2009, 2: 748-757. PMID: 19695543, DOI: 10.1016/j.jcin.2009.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBiomarkersChronic DiseaseCoronary Artery BypassCreatinineDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansKidney DiseasesLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOdds RatioPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsRisk AssessmentTime FactorsTreatment OutcomeTriageConceptsGlycoprotein IIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeBivalirudin monotherapyComposite ischemiaMajor bleedingCoronary syndromeClinical outcomesKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsClinical adverse outcomesCreatinine clearance dataOutcomes of patientsNormal renal functionAdverse event ratesAntithrombotic treatment strategiesSignificant differencesACUITY trialIschemic outcomesRenal functionAdverse outcomesInvasive strategyLate outcomesTreatment strategiesPaclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R. Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal Of Medicine 2009, 360: 1946-1959. PMID: 19420364, DOI: 10.1056/nejmoa0810116.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsFemaleFibrinolytic AgentsFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelRecurrenceRetreatmentRiskStentsSwedenConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsElevation myocardial infarctionTarget lesion revascularizationMyocardial infarctionAngiographic evidenceEnd pointStent thrombosisIschemia-driven target lesion revascularizationPrimary PCIComposite safety end pointIdentical bare-metal stentMajor secondary end pointPrimary end pointSafety end pointSecondary end pointsTarget vessel revascularizationPercutaneous coronary interventionRepeat revascularization proceduresAcute myocardial infarctionSafety outcome measuresDrug-eluting stentsBinary restenosis
2008
Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial
White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW. Safety and Efficacy of Bivalirudin With and Without Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention 1-Year Results From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. Journal Of The American College Of Cardiology 2008, 52: 807-814. PMID: 18755342, DOI: 10.1016/j.jacc.2008.05.036.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsDrug Therapy, CombinationEnoxaparinFemaleFibrinolytic AgentsHeparinHirudinsHumansMaleMiddle AgedPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexRecombinant ProteinsRisk FactorsTime FactorsConceptsIIb/IIIa inhibitorsPercutaneous coronary interventionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsHigh-risk ACS patientsImpact of bivalirudinUnfractionated heparinACUITY trialComposite ischemiaACS patientsCoronary interventionAcute coronary syndrome patientsEfficacy of bivalirudinLess major bleedingSimilar ischemic outcomesAcute coronary syndromeCoronary syndrome patientsBivalirudin monotherapyIschemic outcomesMajor bleedingCoronary syndromeSyndrome patientsBivalirudinPatientsEnoxaparin
2005
Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women
Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. Circulation 2005, 111: 940-953. PMID: 15687113, DOI: 10.1161/01.cir.0000155337.50423.c9.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionCoronary interventionAdjunctive pharmacotherapyHigh-risk acute coronary syndromesContemporary interventional therapyNonfatal ischemic complicationsAcute coronary syndromeAcute myocardial infarctionSex-specific dataCoronary syndromeIschemic complicationsMyocardial infarctionInterventional therapyWomenPharmacotherapyInterventionComplicationsInfarctionSyndromeTherapy
2003
Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent
Mehran R, Aymong ED, Ashby DT, Fischell T, Whitworth H, Siegel R, Thomas W, Wong SC, Narasimaiah R, Lansky AJ, Leon MB. Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent. Circulation 2003, 108: 1078-1083. PMID: 12925457, DOI: 10.1161/01.cir.0000086347.31341.f9.Peer-Reviewed Original ResearchConceptsStent thrombosisIntracoronary stentingNon-Q-wave myocardial infarctionMajor adverse cardiac eventsNative coronary artery lesionsAdverse cardiac eventsBlunt chest traumaPrimary end pointCoronary artery lesionsNative coronary arteriesDevastating clinical consequencesBalloon-expandable stentsAspirin monotherapyAnticoagulation therapyArtery lesionsCardiac eventsChest traumaInfrequent complicationSelect patientsProcedural successRestenotic lesionsCoronary arteryOptimal stentingMyocardial infarctionClinical consequences
2002
A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2])
Kuntz RE, Baim DS, Cohen DJ, Popma JJ, Carrozza JP, Sharma S, McCormick DJ, Schmidt DA, Lansky AJ, Ho KK, Dandreo KJ, Setum CM, Ramee SR, Investigators V. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). The American Journal Of Cardiology 2002, 89: 326-330. PMID: 11809436, DOI: 10.1016/s0002-9149(01)02235-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, Balloon, CoronaryCoronary AngiographyCoronary ThrombosisDisease-Free SurvivalFemaleFibrinolytic AgentsGraft Occlusion, VascularHemorheologyHumansInfusions, Intra-ArterialMaleMiddle AgedThrombectomyTreatment OutcomeUnited StatesUrokinase-Type Plasminogen Activator
1999
Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction
Grines C, Cox D, Stone G, Garcia E, Mattos L, Giambartolomei A, Brodie B, Madonna O, Eijgelshoven M, Lansky A, O'Neill W, Morice M. Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction. New England Journal Of Medicine 1999, 341: 1949-1956. PMID: 10607811, DOI: 10.1056/nejm199912233412601.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionTarget vessel revascularizationAngioplasty groupStent groupMyocardial infarctionPrimary angioplastyCoronary angioplastyStent implantationMean minimal luminal diameterSix-month mortality rateEnd pointCombined end pointPrimary end pointPrimary coronary angioplastyCoronary stent implantationMinimal luminal diameterRoutine implantationClinical benefitMulticenter studyEmergency catheterizationLower incidenceLuminal diameterAngioplastyBlood flowMortality rate